entertainment -WSS

entertainment

author：focus 2025-10-01 15:28:47 - browse：1488

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Adults seen as increasingly susceptible to measles

WSS

EQRx, failed developer of low

Study: Hearing aids may slow cognitive decline in those at risk

Mitch McConnell episode has important public health takeaway

Sage hopes for a blockbuster in antidepressant now before FDA

House passes resolution saying Israel isn't a 'racist or apartheid state'

National panel will explore requiring free Covid tests

focus

entertainment

focus

Tori Bowie and the unacceptable rates of Black maternal death

What to expect as Trump is arraigned on his Jan 6. indictment

Malaria cases in Florida and Texas: Here’s what you need to know

A strong 6.5

New air purifier tech could be key to improving indoor air quality

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Heart attack and stroke risk calculators need revising

A look at other Americans who have crossed into North Korea over the years

Activists slam private health insurers over coverage restrictions

Mega Millions pot grows to $1.25 billion after no winner

explore

New safety details link Apellis eye drug to rare cases of blindness

Sage hopes for a blockbuster in antidepressant now before FDA

Physician groups backed by private equity giant lobby on mergers

Twill hunts for pharma partner to market its depression app

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

entertainment

knowledge

hotspot

Wikipedia